Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Oncotherapy Regulatory News (AVO)

  • This share is currently suspended. It was suspended at a price of 1.925

Share Price Information for Advanced Oncotherapy (AVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.925
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.925
AVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

10 Oct 2016 11:44

RNS Number : 1265M
Advanced Oncotherapy PLC
10 October 2016
 

 

10 October 2016

 

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Directorate Change

 

As mentioned in the annual report for the year ended 31 December 2015 and in the 2016 notice of Annual General Meeting, Advanced Oncotherapy confirms that Mr Kanoria has stepped down from the board of the Company.

 

Advanced Oncotherapy Plc 

www.avoplc.com 

Michael Sinclair, CEO 

Tel: +44 20 3617 8728 

Nicolas Serandour, CFO & COO

 

 

 

Stockdale Securities (Nomad & Joint Broker) 

 

Antonio Bossi / David Coaten 

Tel: +44 20 7601 6100 

 

 

Beaufort Securities (Joint Broker) 

 

Jon Belliss / Elliott Hance

Tel: +44 20 7382 8300

 

 

Walbrook PR (Financial PR & IR) 

Tel: +44 20 7933 8780 or avo@walbrookpr.com 

Paul McManus / Anna Dunphy 

Mob: +44 7980 541 893 / Mob: +44 7876 741 001 

 

 

About Advanced Oncotherapy plc www.avoplc.com 

 

Advanced Oncotherapy is a provider of particle therapy systems with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology providing better health outcomes and fewer treatment related side effects.

 

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology ("LIGHT"). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a linear way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

The Company has signed two purchase agreements for the LIGHT proton therapy systems to be installed in hospitals in China. There are also four additional framework agreements and further Letters of Intent from other healthcare providers.

 

The Company has also signed a joint venture agreement with CircleHealth, owned by AIM-listed Circle Holdings plc, to operate the Company's proton beam cancer therapy centre in Harley Street.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGGPCUUPQGUU
Date   Source Headline
27th Jun 20187:00 amRNSFinal Results
31st May 20187:00 amRNSUpdate on financing
29th May 20187:00 amRNSTechnological update
11th May 20184:35 pmRNSPrice Monitoring Extension
11th May 20187:00 amRNSUpdate on Distribution Agreement Payment
8th May 20187:00 amRNSUK assembly and testing site agreement
26th Apr 20181:50 pmRNSGPSL Research on Advanced Oncotherapy Plc
5th Apr 20187:00 amRNSHolding(s) in Company
3rd Apr 20189:43 amRNSUpdate on Distribution Agreement
12th Mar 20187:15 amRNSHardman & Co Research: Confidence greatly boosted
23rd Feb 20184:05 pmRNSHolding(s) in Company
16th Feb 20187:00 amRNSCompletion of the Subscription Agreement
23rd Jan 201811:48 amRNSResult of Meeting
12th Jan 20187:00 amRNSDirector dealing
28th Dec 20177:01 amRNSNotice of GM
28th Dec 20177:00 amRNSTechnological update
22nd Dec 201711:24 amRNSHolding(s) in Company
13th Dec 20174:25 pmRNSHolding(s) in Company
11th Dec 20172:02 pmRNSHardman Res.: Distribution deal & capital increase
7th Dec 20177:00 amRNSDistribution agreement and Equity Investments
29th Sep 20177:00 amRNSHalf-year Report
4th Sep 20177:00 amRNSTechnological update
1st Aug 20177:00 amRNSDirector Dealing
31st Jul 20177:00 amRNSTechnological milestones update - CCL units
19th Jul 20173:56 pmRNSResult of AGM
19th Jul 201710:16 amRNSFinancing facility by significant shareholders
5th Jul 20177:00 amRNSVideo and update on progress at Harley Street
26th Jun 20177:00 amRNSFinal Results
21st Jun 20177:00 amRNSConversion of Convertible Loan Notes
14th Jun 20177:00 amRNSAppointment of Senior VP of Medical Physics
13th Jun 20177:00 amRNSAdditional financing agreement and new appointment
12th Jun 20177:00 amRNSTechnological milestones update
5th Jun 20172:45 pmRNSUpdate on Bracknor financing
31st May 20174:41 pmRNSHolding(s) in Company
30th May 20177:00 amRNSHarley Street construction update
26th May 20176:23 pmRNSConversion of Convertible Loan Notes
26th May 20177:00 amRNSUpdate on Bracknor financing
24th May 20177:13 amRNSConversion of convertible loan notes
23rd May 201712:01 pmRNSHolding(s) in Company
18th May 20177:31 amRNSConversion of convertible loan notes
16th May 20179:02 amRNSConversion of loan notes
15th May 20171:01 pmRNSDirector Dealing
11th May 20177:00 amRNSDirector Dealing
8th May 20177:00 amRNSIssue of Equity & Director Shareholding
4th May 20177:05 amRNSHolding(s) in Company
3rd May 20171:29 pmRNSHolding(s) in Company
28th Apr 20177:00 amRNSUpdate on Bracknor financing
26th Apr 201711:18 amRNSDirector Dealing
26th Apr 20177:00 amRNSConversion of Convertible Loan Notes
25th Apr 20175:48 pmRNSAdditional financing agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.